MX2017000394A - Vacunas para virus influenza y usos de las mismas. - Google Patents

Vacunas para virus influenza y usos de las mismas.

Info

Publication number
MX2017000394A
MX2017000394A MX2017000394A MX2017000394A MX2017000394A MX 2017000394 A MX2017000394 A MX 2017000394A MX 2017000394 A MX2017000394 A MX 2017000394A MX 2017000394 A MX2017000394 A MX 2017000394A MX 2017000394 A MX2017000394 A MX 2017000394A
Authority
MX
Mexico
Prior art keywords
influenza virus
virus vaccines
influenza
methods
same
Prior art date
Application number
MX2017000394A
Other languages
English (en)
Inventor
Radosevic Katarina
Wilem Meijberg Jan
Wagner Michelle
Ding Zhaoqing
Impagliazzo Antonietta
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017000394(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MX2017000394A publication Critical patent/MX2017000394A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proporcionan polipéptidos de dominio de tallo de hemaglutinina de influenza, métodos para proporcionar polipéptidos de dominio de tallo de hemaglutinina, composiciones que comprenden los mismos, vacunas que comprenden los mismos y métodos para su uso, en particular en la detección, prevención y/o tratamiento de influenza.
MX2017000394A 2014-07-10 2015-07-09 Vacunas para virus influenza y usos de las mismas. MX2017000394A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14176451 2014-07-10
US201462062746P 2014-10-10 2014-10-10
EP14195133 2014-11-27
PCT/EP2015/065661 WO2016005480A1 (en) 2014-07-10 2015-07-09 Influenza virus vaccines and uses thereof

Publications (1)

Publication Number Publication Date
MX2017000394A true MX2017000394A (es) 2017-11-30

Family

ID=55063615

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000394A MX2017000394A (es) 2014-07-10 2015-07-09 Vacunas para virus influenza y usos de las mismas.

Country Status (16)

Country Link
US (2) US10111944B2 (es)
EP (2) EP3587442A1 (es)
JP (1) JP6735269B2 (es)
KR (1) KR102461538B1 (es)
CN (1) CN106661091B (es)
AU (1) AU2015286721B2 (es)
BR (1) BR112017000257A2 (es)
CA (1) CA2952351C (es)
CL (1) CL2017000063A1 (es)
EA (1) EA038400B1 (es)
MX (1) MX2017000394A (es)
MY (1) MY187261A (es)
PE (1) PE20170290A1 (es)
PH (1) PH12016502500A1 (es)
SG (1) SG11201610443WA (es)
WO (1) WO2016005480A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
CA2857087C (en) 2011-11-28 2021-05-25 Crucell Holland B.V. Influenza virus vaccines and uses thereof
JP2016508133A (ja) 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
WO2014191435A1 (en) 2013-05-30 2014-12-04 Crucell Holland B.V. Influenza virus vaccines and uses thereof
AU2015286721B2 (en) 2014-07-10 2019-11-21 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
MY182440A (en) 2014-07-10 2021-01-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
CA3023143A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
SG11202006399VA (en) 2018-01-23 2020-08-28 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
CA3152957A1 (en) 2019-09-05 2021-03-11 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
EA017203B1 (ru) 2006-09-07 2012-10-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
NZ596032A (en) 2009-05-11 2013-09-27 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
WO2013007770A1 (en) 2011-07-14 2013-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
CA2857087C (en) * 2011-11-28 2021-05-25 Crucell Holland B.V. Influenza virus vaccines and uses thereof
WO2014191435A1 (en) * 2013-05-30 2014-12-04 Crucell Holland B.V. Influenza virus vaccines and uses thereof
MY182440A (en) 2014-07-10 2021-01-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
AU2015286721B2 (en) 2014-07-10 2019-11-21 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof

Also Published As

Publication number Publication date
KR102461538B1 (ko) 2022-10-31
US10328144B2 (en) 2019-06-25
MY187261A (en) 2021-09-16
JP2017521425A (ja) 2017-08-03
SG11201610443WA (en) 2017-01-27
US20190015500A1 (en) 2019-01-17
AU2015286721A1 (en) 2016-12-22
PH12016502500A1 (en) 2017-03-22
CN106661091B (zh) 2020-10-30
US10111944B2 (en) 2018-10-30
PE20170290A1 (es) 2017-03-26
BR112017000257A2 (pt) 2017-10-31
EP3587442A1 (en) 2020-01-01
WO2016005480A1 (en) 2016-01-14
AU2015286721B2 (en) 2019-11-21
EA201692541A1 (ru) 2017-05-31
CA2952351C (en) 2023-10-17
KR20170030590A (ko) 2017-03-17
CA2952351A1 (en) 2016-01-14
US20170209564A1 (en) 2017-07-27
EP3166962A1 (en) 2017-05-17
EP3166962B1 (en) 2019-08-21
JP6735269B2 (ja) 2020-08-05
CL2017000063A1 (es) 2017-12-15
EA038400B1 (ru) 2021-08-23
CN106661091A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
PH12016502468B1 (en) Influenza virus vaccines and uses thereof
PH12016502500A1 (en) Influenza virus vaccines and uses thereof
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
IL247309A0 (en) Preparations for inhibiting virus replication and methods for their preparation and use
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
HK1245776A1 (zh) 流感病毒複製抑制劑及其使用方法和用途
MX2015016627A (es) Vacuna para la malaria.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
WO2016007540A3 (en) Compositions and methods for treating dengue virus infection
IL248785B (en) Antecedents of ]-n5,1-dimethyl3--oxo-(3,2-dihydro-h1-pyrazol-4-yl)]-methyl-isoxazole-3-carboxamide and pharmaceutical preparations including these antecedents
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
IL246643A0 (en) Preparations and kits for the treatment of immunodeficiency virus/acquired immunodeficiency syndrome
MX2022004570A (es) Vacunas contra el virus de la gripe y usos de estas.
EP3423107A4 (en) PAN-GENOTYPIC AGENTS AGAINST INFLUENZA VIRUS AND METHODS OF USE THEREOF
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
ZA201700164B (en) Influenza virus vaccines and uses thereof
TH1801002163A (th) เพปไทด์เพื่อใช้ในการรักษาป้องกันและเยียวยาภาวะศีรษะล้าน
UA106905U (uk) Фармацевтична композиція
TH1601001266A (th) วิธีการและองค์ประกอบทางเภสัชกรรมสำหรับการบำบัดการติดเชื้อไวรัสตับอักเสบ b
TH1501001118A (th) ส่วนผสมที่แตกตัวในช่องปากของโวกลิโบส และกระบวนการสำหรับการ จัดเตรียมส่วนผสมนั้น